Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Incyte Corporation    INCY   US45337C1027

INCYTE CORPORATION

 (INCY)
3
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Latest news on INCYTE CORPORATION
3d ago INCYTE CORPORATION: Incyte to Present at Upcoming Investor Conferences
05/03 INCYTE CORPORATION: Incyte to Present at Upcoming Investor Conferences
05/02 INCYTE CORPORATION: SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifie..
05/02 INCYTE CORPORATION: Incyte Reports First-Quarter 2013 Financial Results; Update..
04/29 INCYTE CORPORATION: Incyte Achieves $25 Million Milestone as c-MET Inhibitor IN..
04/26INCYTE CORPORATION: quaterly earnings release
04/23 INCYTE CORPORATION: SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifie..
04/19 INCYTE CORPORATION: SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifie..
04/12 INCYTE CORPORATION: Glancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadl..
04/11 INCYTE CORPORATION: Incyte to Report First Quarter 2013 Financial Results on Ma..
04/05 INCYTE CORPORATION: Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit..
04/02 INCYTE CORPORATION: Law Offices of Todd M. Garber Announces Lead Plaintiff Dead..
03/29 INCYTE CORPORATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Loss..
03/25 INCYTE CORPORATION: Law Offices of Howard G. Smith Announces Lead Plaintiff Dea..
03/18 INCYTE CORPORATION: Innovative Product Portfolios Ride Commercialization & Glob..
03/16 INCYTE CORPORATION: Law Offices of Todd M. Garber Announces Class Action Lawsui..
03/14 INCYTE CORPORATION: Incyte Shareholder Alert: Briscoe Law Firm and Powers Taylo..
03/13 INCYTE CORPORATION: Law Offices of Howard G. Smith Announces Class Action Lawsu..
03/06 INCYTE CORPORATION: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Ag..
02/20 INCYTE CORPORATION: Incyte to Present at Upcoming Investor Conferences
02/14 INCYTE CORPORATION: Incyte Reports 2012 Fourth-Quarter and Full-Year Financial ..
01/24 INCYTE CORPORATION: Incyte to Report Fourth Quarter/Year-End 2012 Financial Res..
2012 INCYTE CORPORATION: Incyte to Present at the 31st Annual J. P. Morgan Healthcar..
2012DJGilead to Pay $510 Million for YM BioSciences to Expand Cancer Portfolio
2012 INCYTE CORPORATION: New Data for Jakafi® (ruxolitinib) Presented at the 2012 Am..
2012 INCYTE CORPORATION: New Data for Jakafi® (ruxolitinib) to Be Presented at the 2..
2012 INCYTE CORPORATION: Incyte to Present at the Oppenheimer 23rd Annual Healthcare..
2012 INCYTE CORPORATION: Incyte to Present at the 24th Annual Piper Jaffray Healthca..
2012 INCYTE CORPORATION: Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inh..
2012 INCYTE CORPORATION: Incyte to Present at the Jefferies 2012 Global Healthcare C..
2012 INCYTE CORPORATION: Incyte Reports 2012 Third-Quarter Financial Results; Update..
2012INCYTE CORPORATION: quaterly earnings release
2012 INCYTE CORPORATION: Jim Daly to Join Incyte as Executive Vice President and Chi..
2012 INCYTE CORPORATION: Incyte to Report Third Quarter 2012 Financial Results on No..
2012 INCYTE CORPORATION: National Myelofibrosis Awareness Day to Launch on September..
2012 INCYTE CORPORATION: Jakavi® (ruxolitinib) First Medication to Receive European ..
2012 INCYTE CORPORATION: Incyte to Present at Upcoming Investor Conferences
2012 INCYTE CORPORATION: Bronstein, Gewirtz & Grossman, LLC Announces Investigation ..
2012 INCYTE CORPORATION: Incyte to Present at the 32nd Annual Canaccord Genuity Grow..
2012 INCYTE CORPORATION: CORRECTING and REPLACING Incyte Reports 2012 Second-Quarter..
2012 INCYTE CORPORATION: Incyte to Report Second Quarter 2012 Financial Results on A..
2012 INCYTE CORPORATION: Incyte to Present at the JMP Securities 7th Annual Healthca..
2012 INCYTE CORPORATION: Incyte Presents Results from a Phase I Trial of INCB024360,..
2012 INCYTE CORPORATION: New Data for Jakafi® (ruxolitinib) Presented at 2012 ASCO A..
2012 INCYTE CORPORATION: Incyte to Present at Upcoming Investor Conferences
2012 INCYTE CORPORATION: Incyte to Present at the Bank of America Merrill Lynch 2012..
2012 INCYTE CORPORATION: Incyte Reports 2012 First-Quarter Financial Results; Update..
2012 INCYTE CORPORATION: Incyte Announces EU Regulatory Milestone for Ruxolitinib
2012 INCYTE CORPORATION: Incyte to Report First Quarter 2012 Financial Results on Ap..
2012 INCYTE CORPORATION: Phase III studies of Jakafi? (ruxolitinib) published in The..
2012 INCYTE CORPORATION: Incyte to Present at Upcoming Investor Conferences
2012 INCYTE CORPORATION: Incyte Reports 2011 Fourth-Quarter and Full-Year Financial ..
2012 INCYTE CORPORATION: Incyte to Present at the Leerink Swann 2012 Global Healthca..
2012 INCYTE CORPORATION: Incyte to Report Fourth Quarter/Year-End 2011 Financial Res..
2011 INCYTE CORPORATION: Incyte to Present at the 30th Annual J. P. Morgan Healthcar..
2011 INCYTE CORPORATION: First FDA-Approved Treatment for Myelofibrosis, Jakafi(TM) ..
2011 INCYTE CORPORATION: First FDA-Approved Treatment for Myelofibrosis, Jakafi™ (ru..
2011 INCYTE CORPORATION: First FDA-Approved Treatment for Myelofibrosis, Jakafi? (ru..
2011 INCYTE CORPORATION: Incyte to Present at the Oppenheimer & Co. 22nd Annual Heal..
2011 INCYTE CORPORATION: Incyte to Present at the 23rd Annual Piper Jaffray Health C..
2011 INCYTE CORPORATION: FDA Approves Incyte's Jakafi(TM) (ruxolitinib) for Patients..
2011 INCYTE CORPORATION: FDA Approves Incyte's Jakafi? (ruxolitinib) for Patients wi..
2011 INCYTE CORPORATION: Incyte Reports Third Quarter 2011 Financial Results and Pro..
2011 INCYTE CORPORATION: Incyte to Report Third Quarter 2011 Financial Results and P..
2011 INCYTE: to Present at Upcoming Investor Conferences
2011 INCYTE: FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis
2011 INCYTE: Reports Second Quarter 2011 Financial Results and Provides Update on Ke..
2011 INCYTE: Reports Second Quarter 2011 Financial Results andProvides Update on Key..
2011 INCYTE: Reports Second Quarter 2011 Financial Results and Provides Update on Ke..
2011 INCYTE: Reports Additional Analyses of Symptomatic Improvement and Quality of L..
2011 INCYTE: Submits New Drug Applicationfor Ruxolitinib in Myelofibrosis to the US ..
2011 INCYTE: Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US..
2011 INCYTE: Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for M..
2011 INCYTE: to Present at Upcoming Investor Conferences
2011 INCYTE: Reports First Quarter 2011 Financial Results and Program Updates
1  2Next
Advertisement
Chart
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Income Statement Evolution
Incyte Corporation : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
My Watchlist|My Portfolio
4-traders.com :
About :
Copyright © 2013 Surperformance. All rights reserved.